Global Health Clinics (MJRX) AI Stock Analysis

• Market Cap: C$328.73K
• Dividend Yield: N/A
• Average Volume (3M): 7.79K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.88
• Revenue Growth: -42.42%
• EPS Growth: -17.33%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 9,392,138
• 10 Day Avg. Volume: 900
• 30 Day Avg. Volume: 7,790
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.02
• Price to Sales (P/S): 1.97
• P/FCF Ratio: -0.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: C$0.03 ▲(70.00% Upside)

The score is driven primarily by very weak financial performance (shrinking revenue, negative profitability, ongoing cash burn) and elevated balance-sheet risk from sustained negative equity and rising debt. Technicals are only neutral with mild recent stabilization, and valuation offers limited support due to negative earnings and no dividend data.

Positive Factors

Cash losses reflect real cash outflows

The close tracking of free cash flow and net income indicates reported losses are realized in cash, not driven by one‑off accounting items. That transparency reduces refinancing risk surprises and gives clearer visibility into runway and true cash needs for 2–6 month planning horizons.

Modest improvement in free cash flow trend

Even a small, positive shift in trailing free cash flow suggests initial operational improvements that could reduce monthly burn if sustained. Over several months this trend can support stabilization, extend runway, and make restructuring or financing options more viable if management sustains the improvement.

Operating in specialty & generic drug sector

The specialty and generic drug industry has structural demand, regulatory barriers to entry, and long product lifecycles. These factors can provide durable revenue opportunities and therapeutic niche positions that, if the company stabilizes operations, support recovery and longer‑term commercialization prospects.

Negative Factors

Material revenue decline

A sharp multi‑period revenue decline erodes fixed‑cost coverage and weakens economies of scale, making recovery harder. Over 2–6 months a shrinking top line constrains reinvestment, undermines bargaining power with partners, and signals potential loss of market share or product demand.

Deep negative profitability

Sustained negative gross and net margins show the business lacks a scalable cost structure. Persistent losses consume cash and equity, limit ability to fund R&D or commercialization, and reduce options for strategic investment or debt repayment over the medium term without significant turnaround.

Highly stressed balance sheet and solvency risk

Negative equity combined with rising debt and a tiny asset base is a structural solvency concern. It restricts access to capital, increases refinancing and covenant risks, and raises dilution or creditor actions as likely outcomes absent durable cash generation improvements over the next several months.

Global Health Clinics Business Overview & Revenue Model

Company Description

Global Health Clinics Ltd. operates in the cannabis industry. The company operates medical clinics, which guide patients through the process of becoming legal users of marijuana. It also engages in developing psilocybin products for research and usage for pharmaceutical purposes. The company was formerly known as Leo Resources Inc. and changed its name to Global Health Clinics Ltd. in August 2018. Global Health Clinics Ltd. was incorporated in 2013 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Global Health Clinics (MJRX) generates revenue primarily through the provision of healthcare services at its clinics. Patients pay for medical consultations, treatments, and health programs either directly or through insurance reimbursements. Additionally, the company may earn income from partnerships with healthcare providers and wellness product suppliers, as well as from offering specialized health programs that could have subscription-based models. The ability to attract and retain patients, as well as maintaining partnerships with insurance companies and healthcare providers, are crucial factors contributing to MJRX's earnings.

Global Health Clinics Financial Statement Overview

Summary

Financials are severely weak: TTM revenue declined 35.9% to 30.6k, gross profit is negative, and net margin is deeply negative (~-43%). The balance sheet is highly stressed with negative equity (~-4.9M) and rising debt (~2.1M) versus a very small asset base (~66k), increasing solvency/dilution risk. Cash flow remains negative with TTM operating cash flow and free cash flow around -584k, indicating continued cash burn.

Income Statement

TTM (Trailing-Twelve-Months) revenue fell to 30.6k (down 35.9%), continuing a multi-year pattern of shrinking sales. Profitability is very weak: gross profit is negative in TTM (and also negative in the latest annual period), and operating and net margins are deeply negative, with TTM net margin around -43%. Losses remain large relative to the revenue base, indicating the business has not found a scalable cost structure yet.

Balance Sheet

The balance sheet is highly stressed with consistently negative shareholders’ equity (about -4.9M in TTM), which is a major solvency red flag. Debt has climbed over time (to ~2.1M in TTM) while total assets are very small (~66k), implying a thin asset base versus obligations. While the debt-to-equity ratio is shown as negative due to negative equity, the underlying takeaway is elevated financial risk and limited balance-sheet flexibility.

Cash Flow

Cash generation remains negative: TTM operating cash flow and free cash flow are both about -584k, indicating ongoing cash burn. A modest positive TTM free cash flow growth is not enough to change the picture given persistent outflows. A relative positive is that free cash flow and net income track closely (both negative), suggesting losses are broadly reflected in cash results rather than being driven by one-time accounting effects.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	47.77K	82.96K	102.85K	146.81K	225.09K
Gross Profit	-515.73K	63.88K	80.64K	116.00K	177.75K
EBITDA	-1.05M	-947.00K	-1.57M	-1.35M	-8.34M
Net Income	-1.27M	-1.08M	-1.63M	-1.37M	-8.48M
Balance Sheet
Total Assets	66.14K	29.33K	241.50K	578.81K	610.60K
Cash, Cash Equivalents and Short-Term Investments	50.48K	9.19K	214.34K	496.69K	456.26K
Total Debt	1.91M	1.52M	1.10M	322.31K	30.81K
Total Liabilities	4.59M	3.29M	2.43M	1.14M	1.05M
Stockholders Equity	-4.53M	-3.26M	-2.18M	-559.58K	-440.39K
Cash Flow
Free Cash Flow	-572.21K	-496.55K	-1.01M	-1.49M	-825.80K
Operating Cash Flow	-572.21K	-496.55K	-1.01M	-1.49M	-825.80K
Investing Cash Flow	0.00	0.00	0.00	0.00	428.97K
Financing Cash Flow	613.50K	291.40K	727.48K	1.53M	763.22K

Global Health Clinics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MJRX, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.48 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MJRX.

Global Health Clinics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GTII	75 Outperform	C$2.29B	38.20	2.42%	―	6.18%	-28.69%
TRUL	60 Neutral	C$2.01B	-10.72	-9.95%	―	4.27%	3.41%
DHT.UN	59 Neutral	C$913.67M	-12.75	-10.92%	3.56%	-0.94%	-540.90%
CURA	58 Neutral	C$2.44B	-6.48	-27.61%	―	-3.38%	-31.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VRNO	49 Neutral	C$2.17B	-4.68	-33.01%	―	-4.58%	-141.91%
MJRX	45 Neutral	C$328.73K	-0.25	―	―	-42.42%	-17.33%